{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:45:02Z","timestamp":1789152302428,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.msard.2025.106540","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:29:58Z","timestamp":1747942198000},"page":"106540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Decoding disease burden in multiple sclerosis: The role of IL-10 as biomarker of neuroinflammation and neurodegeneration"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5679-9833","authenticated-orcid":false,"given":"Eman M","family":"Khedr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-4399","authenticated-orcid":false,"given":"Hussein Bahey","family":"El-Deen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A","family":"El-Mokhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-6227","authenticated-orcid":false,"given":"Doaa M.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106540_bib0001","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/err.err_15_17","article-title":"Correlation of serum interleukin-10 level with disease activity and severity in systemic lupus erythematosus","volume":"45","author":"Abd Elazeem","year":"2018","journal-title":"Egypt. Rheumatol. Rehabil."},{"key":"10.1016\/j.msard.2025.106540_bib0002","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/apm.12659","article-title":"Association of the IL-10 receptor A536G (S138G) loss-of-function variant with multiple sclerosis in Tunisian patients","volume":"125","author":"Ben Fredj","year":"2017","journal-title":"APMIS"},{"key":"10.1016\/j.msard.2025.106540_bib0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1352458517751861","article-title":"2017 McDonald MS diagnostic criteria: Evidence-based revisions","volume":"24","author":"Carroll","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106540_bib0004","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106540_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1132170","article-title":"Are highly active and aggressive multiple sclerosis the same entity?","volume":"14","author":"Correale","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106540_bib0006","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/eji.202149757","article-title":"Multiple sclerosis: immunopathological heterogeneity and its implications","volume":"52","author":"Engelhardt","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2025.106540_bib0007","article-title":"Under the influence: environmental factors as modulators of neuroinflammation through the IL-10\/IL-10R axis","volume":"14","author":"Eryn","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106540_bib0008","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s41983-021-00303-6","article-title":"Reliability and validity of Arabic version of the brief international cognitive assessment for multiple sclerosis: Egyptian dialect","volume":"57","author":"Farghaly","year":"2021","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"10.1016\/j.msard.2025.106540_bib0009","first-page":"410","article-title":"Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis","volume":"95","author":"Fissolo","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106540_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001164","article-title":"Role of chitinase 3-like 1 as a biomarker in multiple sclerosis: a systematic review and meta-analysis","author":"Floro","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106540_bib0011","doi-asserted-by":"crossref","first-page":"1430080","DOI":"10.3389\/fnmol.2024.1430080","article-title":"Interleukin-10 contrasts inflammatory synaptopathy and central neurodegenerative damage in multiple sclerosis","volume":"17","author":"Gilio","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.msard.2025.106540_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u2018real MS","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106540_bib0013","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/01.wnl.0000436065.97642.d2","article-title":"Clinically meaningful performance benchmarks in MS","volume":"81","author":"Goldman","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106540_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.815347","article-title":"Microglia polarization from M1 to M2 in neurodegenerative diseases","volume":"14","author":"Guo","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.msard.2025.106540_bib0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106540_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/cells13242086","article-title":"CHI3L1 in multiple sclerosis-from bench to clinic","author":"Jatczak-Pawlik","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.msard.2025.106540_bib0017","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3390\/cells13242086","article-title":"CHI3L1 in multiple sclerosis\u2014from bench to clinic","volume":"13","author":"Jatczak-Pawlik","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.msard.2025.106540_bib0018","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1007\/s12035-016-9846-x","article-title":"Cytokine profile in patients with progressive multiple sclerosis and its association with disease progression and disability","volume":"54","author":"Kallaur","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.msard.2025.106540_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2023.114756","article-title":"Interleukin 10 (IL10) promoter region polymorphism is associated with IL10 serum concentrations and processing speed in healthy community-dwelling older adults","volume":"458","author":"Keegan","year":"2024","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.msard.2025.106540_bib0020","doi-asserted-by":"crossref","first-page":"54","DOI":"10.47936\/encephalitis.2022.00101","article-title":"Protein biomarkers in multiple sclerosis","volume":"3","author":"Kim","year":"2023","journal-title":"Encephalitis"},{"key":"10.1016\/j.msard.2025.106540_bib0021","article-title":"Inflammatory proteins related to depression in multiple sclerosis: a systematic review and meta-analysis","volume":"43","author":"Kiropoulos","year":"2025","journal-title":"Brain Behav. Immun. - Health"},{"key":"10.1016\/j.msard.2025.106540_bib0022","doi-asserted-by":"crossref","unstructured":"Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). 1983, p. 1444\u20131452.","DOI":"10.1212\/WNL.33.11.1444"},{"key":"10.1016\/j.msard.2025.106540_bib0023","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12974-016-0763-8","article-title":"Balancing the immune response in the brain: IL-10 and its regulation","volume":"13","author":"Lobo-Silva","year":"2016","journal-title":"J Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106540_bib0024","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/153944928500500102","article-title":"Adult norms for the nine hole peg test of finger dexterity","volume":"5","author":"Mathiowetz","year":"1985","journal-title":"Occup. Ther. J. Res."},{"issue":"4","key":"10.1016\/j.msard.2025.106540_bib0025","first-page":"234","article-title":"Photobiomodulation modulates interleukin-10 and interferon gamma production by mononuclear cells from healthy donors and persons with multiple sclerosis","volume":"40","author":"Miguel Angel","year":"2022","journal-title":"Photobiomodul. Photomed. Laser Surg."},{"key":"10.1016\/j.msard.2025.106540_bib0026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/10998004211050082","article-title":"Depression and inflammatory markers in veterans with multiple sclerosis","volume":"24","author":"Newland","year":"2022","journal-title":"Biol. Res. Nurs."},{"key":"10.1016\/j.msard.2025.106540_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/11795735241249693","article-title":"From progression to progress: the future of multiple sclerosis","volume":"16","author":"Oh","year":"2024","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.msard.2025.106540_bib0028","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0022-510X(02)00420-3","article-title":"Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis","volume":"206","author":"Petereit","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106540_bib0029","first-page":"1","article-title":"Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders","volume":"30","author":"Pietro Biagio","year":"2008","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.msard.2025.106540_bib0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1871527315666160615110739","article-title":"Assessment of Interleukin-17A, Interleukin-10 and transforming growth factor-beta1 serum titers in relapsing remitting multiple sclerosis patients treated with avonex, possible biomarkers for treatment response","volume":"16","author":"Rodica","year":"2017","journal-title":"Cns Neurol. Disord.-drug Targets"},{"key":"10.1016\/j.msard.2025.106540_bib0031","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.110899","article-title":"Quality of life in patients with immune-mediated inflammatory diseases","volume":"88","author":"Russell","year":"2011","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.msard.2025.106540_bib0032","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1007\/s10072-023-06764-2","article-title":"Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis","volume":"44","author":"Talaat","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106540_bib0033","article-title":"Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis \u2013 randomized clinical trial","volume":"15","author":"Tamiris","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.msard.2025.106540_bib0034","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jns.2016.07.034","article-title":"Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients","volume":"369","author":"Tawfik","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106540_bib0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106540_bib0036","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/1531-8249(199906)45:6<695::AID-ANA3>3.0.CO;2-R","article-title":"Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis","volume":"45","author":"van Boxel-Dezaire","year":"1999","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106540_bib0037","article-title":"The role of the proinflammatory and anti-inflammatory cytokines in multiple sclerosis","volume":"15","author":"Vani","year":"2022","journal-title":"Biomed. Pharmacol. J."},{"key":"10.1016\/j.msard.2025.106540_bib0038","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1017\/S1355617723007026","article-title":"31 finding the link between inflammatory biomarkers and cognitive functioning in people with multiple sclerosis","volume":"29","author":"Ward","year":"2023","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"10.1016\/j.msard.2025.106540_bib0039","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"10.1016\/j.msard.2025.106540_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00604","article-title":"Low serum interleukin-10 is an independent predictive factor for the risk of second event in clinically isolated syndromes","volume":"10","author":"Wei","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106540_bib0041","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12974-020-01922-1","article-title":"Anti-inflammatory IL-10 administration rescues depression-associated learning and memory deficits in mice","volume":"17","author":"Worthen","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106540_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107322","article-title":"Inflamed\u201d depression: a review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression","volume":"207","author":"Yin","year":"2024","journal-title":"Pharmacol. Res."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:12:21Z","timestamp":1754003541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825002822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":42,"alternative-id":["S2211034825002822"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106540","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding disease burden in multiple sclerosis: The role of IL-10 as biomarker of neuroinflammation and neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106540"}}